Pure Global
NCT00312013

Effects Of Nadroparin In Patients With Lung, Pancreas Or Prostate Cancer

A Randomized, Controlled Trial to Evaluate the Effects of Nadroparin on Survival and Disease Progression in Patients With Advanced Malignancies of the Lung, Pancreas, or Prostate
GlaxoSmithKline·Phase 3·ClinicalTrials.gov·drugCompleted
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Thrombosis, Venous
Drug/Device/Intervention
Nadroparin
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
GlaxoSmithKline
Location
Aalst,Antwerpen,Brasschaat,Bruxelles,Bruxelles,Liège,Roeselare,Toronto,Brno,Praha 2,Praha 5,Praha 5,Praha 8,Pribram,Bethune Cedex,Clermont Ferrand,Lille,Lyon,Marseille,Paris Cedex 13,Paris Cedex 15,Pa, Belgium,Canada,Czech,France,Germany,Hungary,Italy,Netherlands,Poland,Russian Federation,Slovenia
Timeline & enrollment
Phase
Phase 3
Start date
May 01, 2006
End date
Jul 01, 2009
Enrollment
503 participants
Primary outcome

Death due to all causes at study end (patients will be followed until at least Week 46 after randomization).

Summary

This study will evaluate the effects of nadroparin on survival and disease progression in
 patients with hormone-refractory prostate cancer (HRPC), locally advanced pancreatic cancer
 or non-small-cell lung carcinoma (NSCLC).

ICD-10 classifications
Other venous embolism and thrombosisEmbolism and thrombosis of unspecified veinEmbolism and thrombosis of other specified veinsPerianal venous thrombosisArterial embolism and thrombosis
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT00312013
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT00312013 through Pure Global AI's free database. This Phase 3 trial is sponsored by GlaxoSmithKline and is currently Completed. The study focuses on Thrombosis, Venous. Target enrollment is 503 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.